Stopping a GLP-1 medication is common. Sometimes it's a planned decision; sometimes it's a supply gap, a cost change, a pregnancy, a surgery, or a side effect that tips the balance. Whatever the reason, the practical questions are the same: what happens to your body afterward, does how you stop matter, and what should you know before you start again? This guide covers the stopping-and-restarting mechanics. If you're weighing a lower dose against coming off entirely, our companion guide on tapering vs. staying on a maintenance dose covers that comparison directly.
The short version:
- Most people regain much of the weight within a year or so of stopping, and the heart and blood-sugar gains fade with it.
- The regain tends to come back as more fat than muscle, so build strength training and protein in before you stop.
- If you restart after more than a couple of weeks off, expect to step back up through lower doses instead of resuming your old dose.
Why people stop
People come off GLP-1s for a wide range of reasons, and most of them have nothing to do with the medication failing. Insurance coverage lapses or the out-of-pocket cost becomes unsustainable. A supply shortage interrupts refills. Side effects that were tolerable during titration become a persistent burden. Life events such as pregnancy planning, a scheduled surgery, or another health condition make pausing the right call. And some people simply reach a goal and want to try maintaining without medication.
If you're considering it, you're in ordinary company. Real-world data consistently show that long-term use is the exception: across obesity cohorts without diabetes, only about one-third of people are still on therapy at one year, and among people with type 2 diabetes roughly 70% have discontinued by 24 months (Sisodia, The American Journal of Managed Care, 2026, DOI (external link)). A separate real-world cohort of 248 people put numbers to the reasons: about 10% stopped because of non-severe gastrointestinal side effects and about 6% because of cost (Milani et al., Frontiers in Endocrinology, 2026, DOI (external link)).
None of these are wrong reasons, and stopping says nothing about your willpower or commitment. Whatever the reason, though, stopping is a medical decision with predictable physiological consequences, so it helps to know what tends to follow.
What stopping can get you
Most coverage of stopping focuses only on what you lose. The gains are real too.
- Side effects go away. GI effects don't always fade on maintenance. In the STEP 4 trial, nearly half the people who stayed on semaglutide (49.1%) reported gastrointestinal events over 48 weeks, compared with 26.1% of those switched to placebo (Rubino et al., JAMA, 2021, DOI (external link)). If nausea, constipation, or reflux are still affecting your days, stopping or stepping down resolves that.
- Cost and hassle end. No more monthly bills, prior authorizations, pharmacy hunts, or weekly injections.
- Pregnancy planning. Weight-loss medication isn't used during pregnancy. Because semaglutide clears slowly, the Wegovy prescribing information advises stopping at least two months before a planned pregnancy (Wegovy label (external link)). Ask your prescriber for the timing that applies to your specific medication.
- Appetite and food enjoyment come back. For some people, the quieter appetite that helped them lose weight also takes away pleasure in eating, social meals, or cooking. Wanting that back is a legitimate reason.
What stopping doesn't do is improve your health in its own right. Apart from ending side effects, there's no evidence that coming off the medication makes anything better. The research on what happens next is covered below, so you can weigh these gains against it.
What the withdrawal evidence actually shows
The clearest lesson from the research is that these medications treat an ongoing condition: when treatment stops, much of the effect reverses. The STEP 1 trial extension (Wilding et al., 2022) followed people who had lost an average of 17.3% of their body weight on once-weekly semaglutide and then stopped. One year after withdrawal, they had regained roughly two-thirds of that lost weight, and the improvements in blood pressure, cholesterol, and blood sugar drifted back toward where they started (DOI (external link)).
The pattern holds across the drug class. The SURMOUNT-4 trial (Aronne et al., 2024) took people who had lost about 21% of their weight during an open-label tirzepatide lead-in, then randomly assigned some to continue and some to switch to placebo. Over the following year, the placebo group regained about 14% of body weight while those who continued lost a further 5.5%. Continued treatment maintained results, and stopping reversed them (DOI (external link)).
Willpower doesn't explain this. GLP-1 medications work partly by dampening appetite signaling and slowing gastric emptying; when the drug leaves your system, that physiologic support goes with it, and hunger and fullness cues tend to return to their pre-treatment settings. The body also pushes back against weight loss itself. Research on diet-based weight loss estimates that for every kilogram lost, the body burns about 20–30 fewer calories a day while appetite rises by about 100 calories a day, which makes appetite, more than a slowed metabolism, the main driver of regain (Hall and Kahan, Medical Clinics of North America, 2018, DOI (external link)). Those estimates come from dieting studies, not GLP-1 trials, but they describe the pressure the medication had been holding back. The trial authors themselves framed the regain as confirmation that obesity behaves like a chronic condition. Regain is what usually happens, it says nothing about personal failure, and it's the reason to plan any stop ahead of time.
Two more studies add detail to that picture.
STEP 4 tested the question directly: after 20 weeks on semaglutide (an average of 10.6% weight loss), people were randomly assigned to keep going or switch to placebo. Over the next 48 weeks, those who continued lost a further 7.9% of their body weight, while those switched to placebo gained 6.9% (Rubino et al., JAMA, 2021, DOI (external link)).
The largest pooled analysis so far, covering 37 studies and 9,341 people, puts a speed on it. After stopping semaglutide or tirzepatide specifically, weight came back at about 0.8 kg (roughly 1.8 lb) a month. That works out to around 10 kg in the first year, with a projected return to starting weight in about a year and a half. That's faster than after ending a diet-and-exercise program, even when the amount of weight lost was the same. Across all weight-management drugs studied, blood pressure, blood sugar, and cholesterol improvements were projected to return to baseline within about 1.4 years (West et al., BMJ, 2026, DOI (external link)). These are averages, and the authors note that a small proportion of people kept their weight off.
A second 2026 analysis, looking only at GLP-1 drugs, reached a somewhat gentler conclusion about where regain ends up. Modelling six randomized trials with 3,236 people, it found that about 60% of lost weight had returned one year after stopping, with regain slowing over time and levelling off at around 75% of what had been lost. Half of the eventual regain happened within about 23 weeks (Budini et al., eClinicalMedicine, 2026, DOI (external link)). So one analysis projects a full return to starting weight in about a year and a half, and the other projects a plateau that leaves roughly a quarter of the loss in place. They don't truly contradict each other: no large trial has followed people for more than a year after stopping, so both are extrapolating beyond the data, and they use different mathematical curves to do it. They agree on the part that has been measured: most of the regain comes in the first year, and fastest in the first six months.
How much you regain also seems to decide how much of the health benefit you keep. In a follow-up analysis of SURMOUNT-4, people who regained less than a quarter of their lost weight after stopping tirzepatide largely held on to their waist, cholesterol, and insulin improvements. Those who regained three-quarters or more saw their waist grow by about 15 cm and their systolic blood pressure rise by about 10 mm Hg (Horn et al., JAMA Internal Medicine, 2026, DOI (external link)). Repeated stop-and-restart cycles bring their own concern: swings in weight and blood sugar are themselves cardiovascular risk factors, though data on actual heart attacks or strokes after stopping is still sparse (Ceriello et al., Nature Reviews Endocrinology, 2026, DOI (external link)).
What happens in real life, outside trials
Trials measure what happens when people stop and stay off. Real life is messier, and the picture looks different.
A Cleveland Clinic study followed 7,938 people who stopped semaglutide or tirzepatide within 3 to 12 months of starting. Within a year, 19.6% had restarted the same medication and 35.2% had moved to another obesity treatment: a different medication, lifestyle-medicine visits, or, rarely, surgery. On average, people treated for obesity regained just 0.5% of their body weight in the year after stopping, and people treated for type 2 diabetes lost a further 1.3%. The authors stress that individual results varied widely (Gasoyan et al., Diabetes, Obesity and Metabolism, 2026, DOI (external link)).
That doesn't contradict the trials. People in this study had lost less to begin with (8.4% on average for obesity), and many were back on some form of treatment. The lesson is that a stop is often a pause. Research presented at ENDO 2026, based on insurance claims for more than 60,000 adults with type 2 diabetes, found that about 4 in 10 stopped their GLP-1 within a year. Of those who stopped, 41.5% restarted within a year and 58% within two years. This was a conference presentation that hasn't yet been peer-reviewed, and it covers people with diabetes only (Endocrine Society (external link)).
What you regain isn't what you lost
This part gets far less attention than the number on the scale.
Weight lost on a GLP-1 isn't purely fat. A meaningful share is lean mass, including muscle. A 2026 review of what happens around discontinuation reports lean-mass losses averaging roughly 6–7 kg during active treatment, alongside reductions in bone mineral density. The problem is what happens next: the regain that follows stopping is described as fat-preferential, meaning the weight tends to come back disproportionately as fat instead of the muscle you lost (Zeigler et al., Healthcare, 2026, DOI (external link)).
Run that cycle and the scale can return to roughly where it started while your body composition is worse than when you began: less muscle and more fat at the same weight. That's the real cost of an unplanned stop, and it's invisible if you're only tracking pounds.
The same review makes the constructive point. Exercise and medication produce fundamentally different body-composition outcomes: exercise preserves lean mass, bone density, and cardiorespiratory fitness, while pharmacotherapy alone does not. Controlled trial data showed that exercise started during treatment was associated with significantly less weight regain and better sustained weight loss a year after both the medication and the supervised program ended.
The review states two caveats itself. That exercise finding comes from a single liraglutide-based trial and may not transfer cleanly to semaglutide or tirzepatide, and no randomized trial has yet tested exercise specifically at the point of stopping. So treat resistance training and adequate protein as a biologically sound, low-risk bet that hasn't yet been proven as a protocol. The authors reach the same conclusion, as does a parallel nutrition-focused review recommending protein prioritization and resistance-training support around incretin therapy (Zambrano-Villacres et al., Nutrients, 2026, DOI (external link)).
In practice, the best time to start protecting muscle is well before you stop. See why strength training matters, the beginner resistance-training plan, and high-protein meals and snacks when appetite is low.
So is a GLP-1 really a medication for life?
Will I have to take this forever? It's one of the most common questions people ask before they even start. The answer has two parts that pull in different directions.
The case for "yes, for most people." Obesity behaves like other chronic conditions: the treatment works while you take it, and the underlying biology (hunger signaling, metabolic adaptation) doesn't reset when you stop. Every randomized withdrawal trial shows the same pattern, and the BMJ analysis above found no lasting benefit on average by about 1.7 years after stopping any weight-management drug. Its authors concluded that prolonged treatment may be needed to keep the health benefits. By that logic, a GLP-1 is closer to blood pressure medication than to a course of antibiotics.
The case for "not necessarily at full dose, and not for everyone." Averages hide real variation. Some people do keep their weight off after stopping, and nobody can yet predict reliably who they'll be. "Lifelong treatment" also doesn't have to mean the maximum dose every week forever. A 2026 review argued that care should move past the binary of full dose indefinitely or stopping. It suggests aiming for the lowest maintenance intensity that still protects your health, with a clear plan to step back up if weight or markers start moving. It also notes that these approaches still need proper testing (van Bruggen et al., Obesity Pillars, 2026, DOI (external link)).
In practice, the realistic options are:
- Stay on your current dose. This has the strongest evidence for keeping results.
- Step down to a lower maintenance dose. One randomized trial supports this for tirzepatide: people who dropped to 5 mg kept most of their loss, though about 1 in 4 regained at least half of it. See tapering vs. staying on a maintenance dose.
- Switch to a daily pill. One randomized trial found that people moving from an injection to the GLP-1 pill orforglipron kept roughly three-quarters of their loss over a year. It wasn't compared against staying on the injection. See switching from a GLP-1 injection to a pill.
- Space doses further apart. This is off-label with only early evidence; see stretching your dose past 7 days.
- Stop, with a plan and a restart threshold. Expect regain, and decide in advance what would bring you back.
Put simply, the benefits last about as long as some form of effective treatment continues, and what that treatment looks like can change over time.
Tapering vs. stopping abruptly: what's known and not known
A frequent question is whether tapering the dose down before stopping softens the rebound, the way you'd taper off some other medications to avoid withdrawal effects. The evidence here is thin. GLP-1s don't produce a classic physiological withdrawal syndrome, so tapering isn't about preventing that. The large withdrawal trials above studied people who stopped from a full dose; they weren't designed to test whether a gradual taper changes the regain trajectory. So the direct claim "tapering prevents weight regain" isn't something the current published trial evidence establishes one way or the other.
What is reasonable, and what many prescribers do, is treat stepping down to a lower maintenance dose as a distinct strategy from stopping altogether, and there the evidence is more encouraging, as covered in the tapering vs. maintenance guide. A slow step-down may make the transition easier to monitor and adjust, but don't expect tapering alone to hold your weight if the endpoint is zero medication. Building up your non-medication supports (eating patterns, activity, sleep, follow-up) matters more to the outcome than the exact speed of the taper.
A related option people ask about is keeping the same dose but taking it less often, such as every 10 or 14 days. Early reports suggest it may hold results for some carefully selected people, but it hasn't been tested in a randomized trial. We cover the drug-level math and the evidence in stretching your GLP-1 dose past 7 days.
The gap problem: restarting safely
This catches people off guard. If you've been off a GLP-1 for more than a couple of weeks and decide to restart, going straight back to your old full dose is a documented risk for severe gastrointestinal side effects. Your body loses the tolerance it built up during the original titration, so jumping back to a high maintenance dose can bring on the intense nausea, vomiting, or dehydration that slow titration was designed to prevent in the first place.
This is why prescribing information for several of these medications advises re-titrating after an extended gap instead of resuming at the previous dose. The Wegovy injection label, for example, states that if two or more weekly doses in a row are missed, the dose escalation should be restarted at a lower dose, restarting low and stepping back up, which is specifically intended to reduce the GI symptoms that come with reinitiation. A short lapse of a dose or two is a different situation, handled by the standard missed-dose rules; the re-titration concern applies to longer gaps. The exact threshold and schedule vary by drug, so confirm your specific medication's guidance before you restart.
Restarting is common, so plan for it. Given how many people discontinue in the first year, a stop is often a pause, and knowing the re-titration rule in advance makes coming back much more comfortable.
Working with your prescriber
Make decisions about stopping, tapering, and restarting with your prescriber. They can help you plan the transition, set expectations about regain, and get the restart dosing right. Our discussion guide on talking to your doctor about stopping treatment covers how to open that conversation. If a supply gap or cost change is forcing the issue, tell them early: there may be options, such as a lower dose, a bridge, or a structured plan, that beat an abrupt, unmanaged stop.
If you have a say in the timing, the ideal sequence is to get resistance training and your protein intake established while you're still on the medication, so the supports are already running when the appetite suppression comes off.
This guide is general education, not medical advice. Dosing decisions, stopping, and restarting should be made with the prescriber who knows your history. Study findings described here are attributed to their authors, were located via PubMed, and are linked to their original sources by DOI so you can read them in full.